

RESUMEN DE INVESTIGACIÓN

La gravedad de la enfermedad del SARS-CoV-2 y la eficiencia de transmisión aumentan con los aerosoles en los hámsteres sirios, pero no para la exposición a fómites.

J.R. Port et al., bioRxiv: <https://doi.org/10.1101/2020.12.28.424565>

ANTECEDENTES

La investigación experimental ha demostrado que el ARN viral se puede detectar de manera constante hasta siete días en las superficies, pero el virus se degrada rápidamente. Esta discrepancia obstaculiza nuestra capacidad para traducir la detección del ARN del SARS-CoV-2 en las superficies de los hospitales y en muestras de aire y comprender la transmisión y la contribución relativa de los fómites y del virus en el aire.

OBJETIVO

En este estudio se utiliza el modelo de hámster sirio para analizar la contribución relativa de fómites y transmisión aérea y estudiar el impacto de la ruta de transmisión en la gravedad de la enfermedad. Se evalúa el tropismo del SARS-CoV-2, el perfil de diseminación, la gravedad de la enfermedad y la respuesta inmune después de diferentes exposiciones.

MÉTODO

3 grupos de 12 hámsteres cada uno son inoculados con el SARS-CoV-2 por vía nasal, por aerosoles o por fómites. Un cuarto grupo actúa como control. En cada grupo 4 animales son sacrificados el día 1 postinoculación, otros 4 el día cuarto y los restantes el día 14.

RESULTADOS

-La gravedad de la enfermedad clínica se correlaciona con la vía de exposición siendo mayor en aquellos inoculados por aerosoles.

-La exposición a aerosoles deposita virus directamente en el tracto respiratorio superior e inferior, con replicación en el epitelio de la cavidad nasal, epitelio traqueal y bronquial.


-La exposición a fómite SARS-CoV-2 muestra una cinética de replicación retrasada en el tracto respiratorio y conduce a una patología pulmonar menos grave.

-La exposición a fómite SARS-CoV-2 da como resultado un perfil inmunológico y antiinflamatorio más retardado y reducido


-La diseminación viral depende de la vía de exposición.

-El perfil de diseminación temprana puede predecir la gravedad de la enfermedad y la correspondiente respuesta inmunitaria.


-La transmisión aérea es más eficiente que la transmisión por fómite en el hámster sirio.



Títulos de infección por SARS-CoV-2 en función de vía de transmisión



Perfil de diseminación respiratoria en función de la vía de transmisión



Traducido por el Consejo General de Dentistas de España.

Gráficos adaptados del original



CONCLUSIONES

La gravedad de la enfermedad por SARS-CoV-2, así como la transmisión, aumentan cuando los aerosoles son la vía de contagio, en el modelo animal.

1 **SARS-CoV-2 disease severity and transmission efficiency is increased for airborne but not fomite**
2 **exposure in Syrian hamsters.**

3 Julia R. Port^{1*}, Claude Kwe Yinda^{1*}, Irene Offei Owusu¹, Myndi Holbrook¹, Robert Fischer¹,
4 Trenton Bushmaker^{1,2}, Victoria A. Avanzato¹, Jonathan E. Schulz¹, Neeltje van Doremalen¹,
5 Chad S. Clancy³, Vincent J. Munster^{1#}

6
7 1. Laboratory of Virology, Division of Intramural Research, National Institutes of Health,
8 Hamilton, MT, USA

9 2. Montana State University, Bozeman, Montana, USA

10
11 3. Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institutes
12 of Health, Hamilton, MT, USA

13

14

15

16

17 *"These authors contributed equally to this work"

18 #Corresponding author: Vincent Munster, email: vincent.munster@nih.gov

19 **Abstract (150 words or less)**

20 Transmission of SARS-CoV-2 is driven by contact, fomite, and airborne transmission. The
21 relative contribution of different transmission routes remains subject to debate. Here, we show
22 Syrian hamsters are susceptible to SARS-CoV-2 infection through intranasal, aerosol and
23 fomite exposure. Different routes of exposure presented with distinct disease manifestations.
24 Intranasal and aerosol inoculation caused more severe respiratory pathology, higher virus loads
25 and increased weight loss. Fomite exposure led to milder disease manifestation characterized
26 by an anti-inflammatory immune state and delayed shedding pattern. Whereas the overall
27 magnitude of respiratory virus shedding was not linked to disease severity, the onset of
28 shedding was. Early shedding was linked to an increase in disease severity. Airborne
29 transmission was more efficient than fomite transmission and dependent on the direction of the
30 airflow. Carefully characterized of SARS-CoV-2 transmission models will be crucial to assess
31 potential changes in transmission and pathogenic potential in the light of the ongoing SARS-
32 CoV-2 evolution.

33

34 **Keywords:** SARS-CoV-2, animal model, hamster, transmission, coronavirus

35 **Introduction**

36 Since the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in
37 Wuhan, China, in December 2019, the virus has spread across the globe and has caused over
38 70 million cases and 1.5 million deaths as of December 2020 [1]. Infection with SARS-CoV-2
39 can cause asymptomatic to severe lower respiratory tract infections in humans [2, 3]. Peak
40 respiratory shedding in humans occurs at the time of symptom onset or in the week thereafter,
41 followed by a steady decline after the induction of a humoral immune response [4]. To a lesser
42 extent, shedding from the intestinal tract has also been observed, but generally does not appear
43 to be associated with the presence of infectious SARS-CoV-2 nor subsequent transmission.
44 There is no established relationship between COVID-19 disease severity and duration and
45 magnitude of SARS-CoV-2 shedding [5].

46 Considering the scale of the COVID-19 pandemic, it remains unclear to what extent the different
47 routes of exposure contribute to human-to-human transmission and how the exposure route
48 affects disease manifestation. In order to evaluate existing SARS-CoV-2 control measures it is
49 crucial to understand the relative contribution of different transmission routes. Because the
50 majority of cases have been observed in households or after social gatherings, transmission of
51 SARS-CoV-2 is believed to be driven mostly by direct contact, fomites, and short-distance
52 airborne transmission [6]. Airborne transmission can be defined as human-to-human
53 transmission through exposure to large droplets and small droplet nuclei that can be transmitted
54 through the air; whereas airborne transmission includes transmission through both large and
55 small droplets, true aerosol transmission occurs via droplet nuclei particles smaller than 5 μm .
56 Fomites are a result of infectious respiratory secretions or droplets being expelled and
57 contaminating surfaces.

58 In multiple hospital settings SARS-CoV-2 viral RNA has been consistently detected on surfaces
59 [7-12] and air-samples [8, 9, 13-20]. Detection of infectious virus in air and surface samples has
60 been relatively limited, however infectious SARS-CoV-2 has been recovered from air samples

61 [21] and surfaces [22, 23]. Experimental research has shown viral RNA can consistently be
62 detected for up to seven days on surfaces but, the infectious virus degrades rapidly, with limited
63 presence after two days [12]. This discrepancy between the consistent detection of SARS-CoV-
64 2 viral RNA and the relatively short time frames when viable virus can be detected directly
65 hampers our ability to translate SARS-CoV-2 RNA detection on hospital surfaces and in air
66 samples to understanding transmission and relative contribution of fomites and airborne virus.
67 In the current study we use the well-established Syrian hamster model [24-26] to experimentally
68 delineate the relative contribution of fomite and airborne transmission and study the impact of
69 transmission route on disease severity using this model. We evaluated the SARS-CoV-2
70 tropism, shedding profile, disease severity and immune response after different exposures.
71 Using this data, we developed a hamster airborne and fomite transmission model to confirm our
72 findings in a natural transmission setting.

73

74 **Results**

75 **Clinical disease severity is correlated with exposure route**

76 To investigate the impact of exposure route on disease severity, we compared three different
77 inoculation routes. Three groups of 12, 4-6-week-old, female hamsters were inoculated with
78 SARS-CoV-2 via the intranasal (I.N.; 8×10^4 TCID₅₀), aerosol (1.5×10^3 TCID₅₀) or fomite (8×10^4
79 TCID₅₀) routes (Fig 1 a). An unexposed control was included (N = 12) as comparison. For each
80 group, 4 animals were euthanized on 1 day post inoculation (DPI) and 4 DPI, the remaining 4
81 animals were monitored until 14 DPI. Animals inoculated via the I.N. or aerosol routes
82 demonstrated significant weight loss, whereas fomite exposure resulted in limited, transient
83 weight loss. Animals inoculated I.N. started losing weight at 3 DPI and aerosol exposed animals
84 at 2 DPI (Fig 1 b). Weight loss at 6 DPI was significant compared to unexposed controls for I.N.,
85 and at 4 DPI for aerosol group (Fig 1 b; N = 4, Mann-Whitney test, $p = 0.0286$ and $p = 0.0286$).
86 In addition to weight loss, inconsistent, temporary, mild lethargy and ruffled fur were observed.

87 Fomite exposure presented with less weight gain compared to unexposed controls. At 14 DPI
88 no significant difference was observed between the groups (Fig 1 c; N = 4, Kruskal-Wallis test,
89 followed by Dunn's multiple comparison test, $p = 0.2953$).

90

91 **Aerosol exposure directly deposits virus in the upper and lower respiratory tract, with**
92 **replication in the nasal cavity epithelium, tracheal and bronchial epithelia**

93 Early (1 DPI) SARS-CoV-2 tropism and replication were investigated for each exposure route.
94 Infectious virus could be detected in the trachea of all I.N. and aerosol exposed animals. In the
95 lung, infectious virus was detected in all aerosol exposed animals and a subset of I.N.
96 inoculated hamsters (Fig 1 d). No infectious virus was detected at 1 DPI in the fomite group in
97 either the upper or lower respiratory tract. Compared to I.N. exposed animals, aerosol exposed
98 hamsters demonstrated significantly increased viral load in the trachea and the lung at this time
99 point (N = 4, ordinary two-way ANOVA, followed by Tukey's multiple comparisons test, $p =$
100 0.0115 and $p = <0.0001$, respectively). This suggests that aerosol exposure more efficiently
101 deposits viral droplet nuclei in the lower respiratory system. No infectious virus was detected in
102 the gastrointestinal tract regardless of the route of inoculation.

103 To investigate initial cellular tropism, immunohistochemistry (IHC) targeting the SARS-CoV-2
104 nucleoprotein as a marker of SARS-CoV-2 replication was performed on skull sagittal sections
105 and lung sections at 1 DPI. In aerosol inoculated animals, viral antigen was observed in
106 moderate to numerous ciliated epithelial cells in the nasal cavity, tracheal mucosa, and
107 bronchiolar mucosa. In addition, viral antigen was detected in type I and type II pneumocytes,
108 pulmonary macrophages and olfactory epithelial cells (Fig 2 a, e, i, m). Comparatively,
109 evaluation of I.N. exposed hamsters revealed a lack of viral antigen in the epithelial cells of the
110 trachea and lung at this timepoint. Interestingly, viral antigen was detected in pulmonary
111 macrophages in a subset (N= 2/4) of I.N. inoculated hamsters at 1 DPI. Viral antigen was
112 detected in ciliated and olfactory epithelium of the nasal turbinates (Fig 2 b, f, j, m). In

113 accordance with the virological findings, no SARS-CoV-2 antigen was detected in the trachea or
114 lung of any fomite inoculated hamsters (N = 0/4). Viral antigen was detected in ciliated epithelial
115 cells of the nasal turbinates in one (N = 1/4) fomite inoculated hamster (Fig 2 c, g, k, m). No
116 SARS-CoV-2 antigen was detected in the esophagus or brain in any of the evaluated animals
117 (data not shown) nor in unexposed control tissues (Fig 2 d, h, l, m).

118

119 **Fomite SARS-CoV-2 exposure displays delayed replication kinetics in the respiratory**
120 **tract and leads to less severe lung pathology**

121 To determine the correlation between exposure route and subsequent respiratory tract
122 pathology, sections of lung, trachea and nasal turbinates were obtained for histopathological
123 evaluation at 1 and 4 DPI. Interestingly, nasal turbinate pathology was observed in a subset of
124 hamsters regardless of inoculation route at 1 DPI (Fig 3 a, b, c). Histopathologic lesions were
125 observed primarily in ciliated epithelial cells at 1 DPI and were most consistently observed in the
126 I.N. inoculation group with all (N = 4/4) inoculated animals exhibiting mild to moderate ciliated
127 epithelial cell necrosis with influx of numerous degenerate and non-degenerate leukocytes
128 followed closely by aerosol inoculated hamsters with 75% (N = 3/4) exhibiting minimal to
129 moderate pathology. The fomite inoculation group had the least consistent and least severe
130 histopathologic lesions in the nasal turbinates with half (N = 2/4) of hamsters having no
131 histopathologic lesions and the remaining hamsters (N = 2/4) having only minimal pathology.
132 Mild to moderate tracheal inflammation was observed in all (N = 4/4) aerosol inoculated and half
133 (N = 1/2) of the I.N. inoculated hamsters (Fig 3 e, f). Tracheal inflammation was not observed in
134 any of the fomite inoculated hamsters (N = 4; Fig 3 g), confirming that virus titers detected at 1
135 DPI are linked to early-onset pathological changes in this model. As expected, pulmonary
136 pathology was minimal (aerosol and fomite) at 1 DPI, regardless of route of inoculation. Early
137 histopathologic lesions in the lung included rare single cell bronchiolar epithelial cell necrosis,
138 infiltration of rare or low numbers of neutrophils into the bronchiolar mucosa and focal interstitial

139 pneumonia with minimal septal expansion by edema fluid and spillover of rare leukocytes into
140 the adjacent alveolar spaces (Fig 3 i, j, k).

141 By 4 DPI, infectious virus could be detected in the lung of all animals regardless of inoculation
142 route. No significant difference was observed between I.N. and aerosol or fomite exposed
143 animals (Fig 1 d; N = 4, ordinary two-way ANOVA, followed by Tukey's multiple comparisons
144 test, $p = 0.4114$ and $p = 0.9201$, respectively). An increase in the severity of both turbinate and
145 pulmonary pathology was observed in all evaluated hamsters regardless of the route of
146 inoculation. Interestingly, in both aerosol and I.N. inoculation routes, regions of olfactory
147 epithelium within the nasal turbinates were more severely affected, suggesting initial viral
148 attachment and replication in ciliated epithelium followed by targeting of the more caudal
149 olfactory epithelium during disease progression (Fig 3 m, n, o). At this timepoint, nasal mucosal
150 pathology was observed in all fomite inoculated animals. However, the pathology was less
151 severe as compared to I.N. and aerosol groups and focused primarily on regions of ciliated
152 mucosa, suggesting a delay in disease progression relative to aerosol and I.N. routes. Tracheal
153 inflammation was observed in all inoculation routes and varied from minimal to mild (Fig 3 q, r,
154 s). Moderate pulmonary pathology consistent with previously described SARS-CoV-2 infection
155 in Syrian hamsters [24] was observed in aerosol and I.N. inoculated animals at 4 DPI (Fig 3 u,
156 v) with less severe and less consistent pathology observed in the fomite inoculation group (Fig 3
157 w). Lesions were characterized as moderate, broncho-interstitial pneumonia centered on
158 terminal bronchioles and extending into adjacent alveoli. The interstitial pneumonia was
159 characterized by thickening of alveolar septa by edema fluid, fibrin and moderate numbers of
160 macrophages and fewer neutrophils. Inconsistent pulmonary pathology was observed for this
161 group with lesions ranging from minimal to moderate, which is in accordance with the
162 observation that some fomite exposed animals did demonstrate high viral loads in the lung at 4
163 DPI (Fig 3 w). No significant histopathologic lesions were observed in sections of mediastinal

164 and mesenteric lymph node, esophagus, duodenum, or colon, (data not shown) or any control
165 animal on 1 and 4 DPI (Fig 3 d, h, l, p, t, x).

166 Using a hierarchical clustering of lung pathology parameters (bronchiolitis, interstitial
167 pneumonia, tracheitis, pathology of the ciliated and olfactory epithelium) on both 1 and 4 DPI in
168 relation to the observed viral titers, a clear relationship existed between the respiratory
169 pathology at 1 DPI in the trachea, and viral load of trachea and lung, while pathology in the
170 nasal epithelial was more distantly related (Fig 3 y). Of note, viral load in the lungs at 4 DPI was
171 most closely associated with presentation of interstitial pneumonia. Fomite exposed animals
172 most closely resembled unexposed controls at 1 DPI and clustered together as a separate
173 group at 4 DPI due to the appearance of tracheitis, pathology in the ciliated epithelium without
174 distinct lower respiratory tract involvement (Fig 3 z). This implies that fomite SARS-CoV-2
175 exposure displays delayed replication kinetics in the respiratory tract and leads to less severe
176 lung pathology at 4 DPI compared to direct deep deposition of virus into the respiratory tract
177 (aerosol inoculation).

178

179 **Fomite SARS-CoV-2 exposure results in a delayed, reduced, and anti-inflammatory** 180 **immune profile**

181 To investigate the systemic immune response, cytokine specific ELISAs were performed on
182 serum at 4 DPI (Fig 4 a). Expression patterns were strikingly different depending on exposure
183 route for pro-inflammatory tumour necrosis factor (TNF)- α and anti-inflammatory IL-4 and IL-10.
184 Both I.N. and aerosol groups presented with increased levels of TNF- α at 4 DPI as compared to
185 unexposed animals, whilst the fomite exposed group demonstrated decreased levels; a
186 significant difference in serum levels was detected between I.N. and fomite exposed groups (N
187 = 4, Kruskal-Wallis test, followed by Dunn's multiple comparisons test, $p = 0.0360$). Adversely,
188 the IL-4 levels were markedly increased in all groups as compared to unexposed animals, yet

189 highest levels were seen in fomite exposed animals, the difference between unexposed and
190 fomite group reaching statistical significance (N = 4, Kruskal-Wallis test, followed by Dunn's
191 multiple comparisons test, $p = 0.0109$). Increased serum IL-10 was also observed in fomite
192 exposed animals and I.N. exposed animals, while a decrease was observed in animals after
193 aerosol exposure, resulting in a significant difference between aerosol and fomite exposed
194 hamsters (N = 4, Kruskal-Wallis test, followed by Dunn's multiple comparisons test, $p = 0.0286$).
195 While not significant, a trend of decreased serum levels of interferon (INF)- γ as compared to
196 uninfected animals, was observed. No significant differences were seen for serum levels of
197 interleukin (IL)-6.

198 Irrespective of exposure route, all exposed animals seroconverted at 14 DPI as seen by the
199 presence of antibodies targeting the SARS-CoV-2 spike measured by ELISA (Fig 4 b). The
200 magnitude of humoral response was linked to the exposure route. I.N. exposure resulted in the
201 strongest, and significantly higher antibody response when compared to fomite exposure (N = 4,
202 Kruskal-Wallis test, followed by Dunn's multiple comparisons test, $p = 0.0209$). No significant
203 difference was observed between I.N. and aerosol exposed animals. Taken together this
204 suggests a predominantly anti-inflammatory immune response is mounted after fomite
205 exposure, as compared to aerosol exposure, which may protect from more severe outcome, yet
206 is also linked to a weaker, but still substantial, antibody response.

207

208 **Viral shedding is exposure route dependent**

209 To gain an understanding of route-dependent virus shedding patterns of SARS-CoV-2 in the
210 Syrian hamster, daily oropharyngeal and rectal swabs were taken until 7 DPI, after which swabs
211 were taken thrice weekly (Fig 4 c, d). Oropharyngeal swabs are a measurement of respiratory
212 shedding while rectal swabs assess intestinal shedding. Viral sgRNA, a marker of virus
213 replication [27], was detected in both swabs from all exposed animals on at least one day.
214 When comparing the overall respiratory shedding profile between the exposure routes, different

215 patterns were observed. I.N. inoculation resulted in high viral loads starting at 1 DPI and
216 continued up until 6 DPI, before sgRNA levels started to decrease. In the aerosol inoculated
217 group, the peak of virus shedding was reached on 2 DPI and viral sgRNA levels decreased
218 immediately thereafter. In contrast, animals exposed through the fomite route demonstrated
219 different shedding kinetics as compared to aerosol and I.N. groups with an increase in viral
220 sgRNA shedding over multiple days, until peak shedding was reached at 5 DPI. While a trend
221 seemed present for higher individual peak shedding in I.N. and fomite groups, no significant
222 difference was detected (Fig 4 e; N = 4, Kruskal-Wallis test, followed by Dunn's multiple
223 comparisons test, $p = 0.8400$). In comparison, intestinal shedding demonstrated median lower
224 viral loads with no significant difference between groups: N = 4 Kruskal-Wallis test, followed by
225 Dunn's multiple comparisons test, $p = 0.1512$ (Fig 4 d, e). Looking at the shedding profile of
226 individual animals across groups, intestinal shedding was observed for a maximum of three
227 consecutive days with sgRNA only being detected in swabs for one or two consecutive days for
228 most positive animals. To evaluate the overall shedding burden generated by each exposure
229 route, the cumulative shedding up until 14 DPI (area under the curve (AUC)) was compared.
230 Aerosol exposure led to overall less viral RNA in oropharyngeal swabs as compared to I.N. and
231 fomite exposure (N = 4, Kruskal-Wallis test, followed by Dunn's multiple comparisons test, $p =$
232 0.0263). In contrast, most commutative viral sgRNA was detected in rectal swabs of aerosol
233 exposed animals (Fig 4 f). Taken together, these data suggest that severity of disease is not
234 indicative of the duration and cumulative amount of virus shed after infection.

235

236 **Early shedding profile may predict disease severity and corresponding immune** 237 **response**

238 As we observed different impacts on disease profiles between exposure routes, we next
239 investigated potential predictability of disease through early shedding patterns. Cytokine
240 responses as a measurement of the immune status (4 DPI) were included in the correlations

241 between early shedding (2 DPI), peak shedding, peak weight loss, lung titers and pathology at 4
242 DPI (Fig 3 g). Lung viral titers were positively correlated significantly with the amount of viral
243 RNA detected in oropharyngeal swabs at 2 DPI (Spearman correlation test, $N = 12$, $p = 0.047$).
244 Lung titers showed a positive relationship with upper and lower respiratory tract pathology and
245 weight loss. This suggests that early time point respiratory shedding (before disease
246 manifestation) may predict the acute disease manifestation.

247 Serum levels of IL-4, IL-6 and IL-10 did not show any significant correlations with parameters of
248 disease severity; however, a clear negative relationship could be seen in the correlations. TNF-
249 α , negatively correlated to IL-4 and IL-10 levels (Spearman correlation test, $N = 12$, $p = 0.048$
250 and $p = 0.049$, respectively). A positive correlation between early rectal shedding and TNF- α
251 serum levels and olfactory pathology was observed (Spearman correlation test, $N = 12$, $p =$
252 0.0002 and $p = 0.001$, respectively) (Fig 4g).

253

254 **Airborne transmission is more efficient than fomite transmission in the Syrian hamster**

255 To investigate viral fomite contamination of caging, daily swabs were taken from surfaces in
256 cages containing one I.N. inoculated hamsters, up to 7 DPI (Sup Fig 1 b, c). Viral gRNA was
257 detectable at 1 DPI in all samples, sgRNA was detectable for 7/8 (87.5%) bedding samples and
258 3/8 (37.5%) cage samples, and at 2 DPI in 8/8 cages for both samples. Viral sgRNA was
259 detectable at high concentrations up until 7 DPI, with peak concentrations seen on 2 and 3 DPI,
260 suggesting a robustly contaminated caging environment.

261 To assess the potential risk of fomite transmission, we introduced sentinel hamsters to cages
262 after housing two I.N. infected animals for 4 days. (Fig 5 a). No signs of disease or weight loss
263 were observed in sentinel animals, but seroconversion was seen in 4 out of 8 animals (Fig 5 f)
264 at 21 days after exposure (DPE) to a contaminated cage, confirming that hamster-to-hamster
265 indirect transmission via fomites can occur (Fig 5 h).

266 Next, the efficiency and dynamics of airborne hamster-to-hamster transmission were assessed.
267 For this purpose, we designed a cage divider, which allowed airflow but no direct contact or
268 fomite transmission between animals. (Fig 5 b, Fig 5 c, d, and supplemental video). We used a
269 particle sizer to assess the effect of the cage divider on blocking particle flow. We observed that
270 cross-over of smaller particles ($<10\ \mu\text{m}$) was blocked approx. 60%, whilst larger particles (>10
271 μm), were reduced over 85% on the sentinel side (Fig 5 d, e).

272 In the first experiment, one sentinel hamster was placed on the side of the divider downflow
273 from one infected animal (N = 8). In contrast to animals exposed directly to aerosolized virus, no
274 signs of disease or weight loss were observed in any of the sentinel animals (Fig 5 g). However,
275 all animals seroconverted. To assess the importance of directional airflow, airborne
276 transmission was also modeled for 4 transmission pairs housing the sentinel against the airflow
277 (Fig 5 b, c). Only one out of 4 of the sentinels placed against airflow seroconverted (Fig 5 g),
278 suggesting, as expected, that directional airflow is key to airborne transmission. When
279 comparing the antibody response at 21 DPI/DPE, no significant difference was
280 determined between the donor I.N. inoculated animals and those that seroconverted
281 after airborne transmission (100%), while titers for animals that seroconverted after
282 fomite transmission (50%) were lower (Fig 5 g, Kruskal-Wallis test, followed by Dunn's
283 multiple comparisons test, N = 8 and N = 4, $p = >0.9999$ and $p = 0.2488$, respectively).
284 Titers were comparable to those observed after direct inoculation. Together, this
285 suggests that hamster-to-hamster airborne transmission may present with
286 asymptomatic disease manifestation, yet the humoral immune memory is comparably
287 robust.

288 To investigate the transmission risk posed by animals after fomite or airborne transmission, the
289 respiratory shedding profile was determined. Viral shedding was demonstrated in 4 out of 8

290 sentinel hamsters after exposure to contaminated cages on multiple consecutive days.
291 Shedding was observed at 1 DPE, with peak viral sgRNA being seen at 4/5 DPE, like what was
292 observed in hamsters directly exposed to fomites (Fig 4 c). For airborne transmission, sentinels
293 downstream of airflow started shedding by 1 DPE, and all 8 animals had high amounts of viral
294 sgRNA in the oropharyngeal cavity by 2 DPE, which remained high until 6 DPE. This data
295 suggest that this indirect exposure route presents with a distinctly different disease
296 manifestation and shedding profile than direct aerosol exposure (Fig 5 i). Of note, commutative
297 viral shedding between infected airborne exposed animals showed no difference to those
298 infected through fomite transmission (Fig 5 j). These data imply that, whilst presenting with no or
299 very mild disease phenotypes, both routes of indirect exposure between animals create a
300 mimicry of asymptomatic carriers.

301

302 **Discussion**

303 SARS-CoV-2 transmission is driven by close proximity, confined environment, and the
304 frequency of contacts [28]. Infection with SARS-CoV-2 is believed to be driven by direct contact,
305 inhalation of virus within respiratory droplet nuclei, contact with droplet contaminated surfaces or
306 any combination between these exposures. Yet, the relative contribution of each of the potential
307 routes of exposure in relationship to human-to-human transmission has been elusive. Moreover,
308 the relationship between exposure route and the differential impact on disease severity has
309 been equally obscure. Animal models are essential to model experimental transmission under
310 controlled conditions, as transmission involves several factors: duration and magnitude of virus
311 shedding, stability of the virus in aerosols or on surfaces, and the subsequent infection of
312 another host.

313

314 Our data indicate that in addition to the exposure dose [29] and underlying host conditions [30],
315 disease is a function of exposure route. The Syrian hamster model recapitulates several

316 aspects of COVID-19, including upper and lower respiratory tract pathology, SARS-CoV-2
317 shedding and potential transmission between animals [24-26, 29, 31-33]. Typically,
318 experimental studies with SARS-CoV-2 in hamsters rely on intranasal inoculation. This route of
319 inoculation establishes robust infection but does not resemble natural infection via aerosols or
320 respiratory droplets. Here we directly compared natural transmission routes, designed to mimic
321 airborne and fomite exposure. The initial respiratory tropism of SARS-CoV-2 was determined by
322 the exposure route, aerosol exposure deposited SARS-CoV-2 more efficiently in both the upper
323 and lower respiratory tract. As a result, the SARS-CoV-2 replication kinetics displayed higher
324 viral titers in trachea and lung early in the infection compared to the I.N. inoculated animals.
325 Despite a 10-fold lower inoculation dose, exposing Syrian hamsters to aerosolized SARS-CoV-2
326 resulted in more rapid virus replication in the lung and weight loss compared to I.N. inoculation.
327 In contrast, fomite inoculation displayed a delayed disease manifestation with a prolonged time
328 between exposure and viral replication in the lung leading to reduced disease severity. This
329 delay suggests that for fomite infection viral replication may occur in the oropharynx before
330 being inhaled [32]. It's possible that this may give time for a regulating immune response
331 characterized by a systemic lack of TNF- α and an increased IL-4 and IL-10 presence
332 demonstrated in this work. This in turn may reduce immune pathology in the lung even with the
333 observed viral titers at 4 DPI not being significantly lower as compared to aerosol inoculation.
334
335 No human data is currently available on the influence of transmission route on COVID-19
336 severity. In experimental Nipah virus infection studies in non-human primates, particle size
337 directly influenced the disease manifestations. Aerosol exposure led to a rapidly progressing
338 respiratory disease whereas large droplet exposure led to an extended disease course that
339 does not have the prominent respiratory features [34, 35]. These findings suggest more severe
340 disease is associated with direct deposition of the virus in the lower respiratory tract, whereas
341 with milder disease the first viral replication occurs in upper respiratory tract. This further implies

342 that besides lowering viral dose, intervention measures such as face-coverings may also serve
343 to minimize disease by limiting the deposition of viral particles into the lower respiratory tract
344 [36-38]. More investigations are required to validate if this occurs [39].

345 Our data reflects findings in humans, where no clear correlation could be drawn between
346 severity of disease and shedding time. The aerosol exposed animals shed cumulatively less
347 virus, while fomite exposure resulted in equally high peak viral shedding compared to I.N.
348 inoculated animals. In humans, serological analyses suggest that approximately 17% of
349 infections remain mild to asymptomatic [40]. There is evidence of both asymptomatic and
350 symptomatic shedding [41-44], suggesting that mild or asymptomatic disease contribute the
351 same transmission risk as more severe COVID-19 cases [45, 46]. Asymptomatic disease in
352 humans may present with lower shedding dose or faster decline [5], which we did not observe in
353 this animal model.

354 The relative contribution of fomite and airborne transmission to the spread of SARS-CoV-2 is
355 still disputed [47]. The risk of fomite transmission was previously assessed as lower compared
356 to airborne transmission in a limited study in the Syrian hamster. Fomite transmission occurred
357 in only 1 of 3 sentinels placed into contaminated cages at viral RNA peak contamination [25].
358 Surprisingly, we demonstrate here that fomite transmission may still occur (4 out of 8) when
359 peak shedding of infectious virus has waned as previously shown [25], and environmental
360 contamination is expected to be reduced. Importantly, this implies that even with an increased
361 understanding of airborne transmission involvement at this stage of the pandemic, the risk of
362 fomite transmission in humans should not be underestimated. In particular, fomite transmission
363 may be more likely to occur in nosocomial settings that present a combination of fomite and
364 aerosol generating procedures and may potentially be further enhanced with more susceptible
365 hospital population [48, 49].

366 Within our transmission set-up we show a selective reduction of largest particles ($>10\ \mu\text{m}$), but
367 that this exclusion was not absolute (Fig 5). Therefore, we cannot formally distinguish between
368 true aerosol transmission (droplet nuclei $< 5\ \mu\text{m}$), droplet transmission ($> 10\ \mu\text{m}$), or a
369 combination of these two. Previous studies have shown that SARS-CoV-2 can be transmitted
370 through the air in a ferret model over short and moderate distance [50, 51] and in hamsters over
371 short distance [25, 52]. In our study we were able to show a high efficiency of airborne
372 transmission with 100% of the sentinels becoming infected. When reversing the airflow from
373 uninfected animals toward infected animals, a sharp reduction in transmission was observed.
374 This suggest that directional airflow plays an important role in the transmission of SARS-CoV-2.
375 This has also been observed in human-to-human transmission events, where transmission in
376 confined spaces (e.g. restaurant) was directed by airflow [16, 53, 54]. Control measures focused
377 on strategically designed room ventilation will directly aid the control of the pandemic [55, 56].

378 In this study, we showed the relative contribution of airborne and fomite transmission and the
379 impact of exposure route on disease. The hamster transmission model will be crucial to assess
380 the transmission and pathogenic potential of novel SARS-CoV-2 strains, in the light of the
381 continuing SARS-CoV-2 virus evolution [57]. In addition, this work will allow the development of
382 effective public health countermeasures aimed at blocking human-to-human transmission. The
383 findings of this study suggest that using more natural routes of transmission are highly suitable
384 for accurately assessing the transmission potential and pathogenicity of novel evolved strains
385 [57]. Additionally, these data strongly suggest that the Syrian hamster model would be very
386 suitable to investigate the true limits of airborne transmission and applying this to prevention
387 studies as has been previously demonstrated for short distance airborne transmission with
388 masks [52]. Furthermore, demonstrating hamster-to-hamster natural transmission via different
389 routes indicates that this model is useful for setting up complex intervention experiments
390 involving different transmission routes.

391

392 **Materials and Methods**

393 *Ethics statement*

394 Approval of animal experiments was obtained from the Institutional Animal Care and Use
395 Committee of the Rocky Mountain Laboratories. Performance of experiments was done
396 following the guidelines and basic principles in the United States Public Health Service Policy on
397 Humane Care and Use of Laboratory Animals and the Guide for the Care and Use of Laboratory
398 Animals. Work with infectious SARS-CoV-2 strains under BSL3 conditions was approved by the
399 Institutional Biosafety Committee (IBC). Inactivation and removal of samples from high
400 containment was performed per IBC-approved standard operating procedures.

401

402 *Virus and cells*

403 SARS-CoV-2 strain nCoV-WA1-2020 (MN985325.1) was provided by CDC, Atlanta, USA. Virus
404 propagation was performed in VeroE6 cells in Dulbecco's Modified Eagle Medium (DMEM)
405 supplemented with 2% foetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin and
406 100 µg/mL streptomycin. Cells were cultured in DMEM supplemented with 10% FBS, 2 mM L-
407 glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin. No contaminants were detected;
408 the used virus was 100% identical to the initial deposited GenBank sequence (MN985325.1).

409

410 *Inoculation experiments*

411 Four to six-week-old female Syrian hamsters (ENVIGO) were inoculated (12 animals per route)
412 either intranasally (I.N.), via aerosol exposure or via exposure to a fomite. Hamsters were
413 housed in groups of 4 animals. I.N. inoculation was performed with 40 µL sterile DMEM
414 containing 8×10^4 TCID₅₀ SARS-CoV-2. For exposure through aerosols animals were subjected
415 to 1.5×10^3 TCID₅₀ SARS-CoV-2 during a 10 min exposure time. Aerosol inoculation using the
416 AeroMP aerosol management platform (Biaera technologies, USA) was performed as described

417 previously [58]. Briefly, non-anesthetized hamsters were exposed to a single exposure whilst
418 contained in a stainless-steel wire mesh cage. Aerosol droplet nuclei were generated by a 3-jet
419 collision nebulizer (Biaera technologies, USA) and ranged from 1-5 μm in size. Respiratory
420 minute volume rates of the animals were determined using the methods of Alexander *et al.* [59].
421 Weights of the animals were averaged and the estimated inhaled dose was calculated using the
422 simplified formula $D = R \times C_{\text{aero}} \times T_{\text{exp}}$ [60], where D is the inhaled dose, R is the respiratory
423 minute volume (L/min), C_{aero} is the aerosol concentration (TCID₅₀/L), and T_{exp} is duration of the
424 exposure (min). Fomite exposure was conducted by placing a polypropylene dish into the cage
425 containing 40 μL of 8×10^4 TCID₅₀ SARS-CoV-2 per hamster (total dose per cage: 3.2×10^5
426 TCID₅₀).

427 At 1- and 4-days post infection (DPI), four hamsters for each route were euthanized, and tissues
428 were collected. The remaining 4 animals for each route were euthanized at 14 DPI for disease
429 course assessment and shedding analysis. Hamsters were weighted daily, and oropharyngeal
430 and rectal swabs were taken daily until day 7 and then thrice a week. Swabs were collected in 1
431 mL DMEM with 200 U/mL penicillin and 200 $\mu\text{g}/\text{mL}$ streptomycin. Hamsters were observed daily
432 for clinical signs of disease.

433

434 *Airborne Transmission experiments*

435 Airborne transmission was examined by co-housing hamsters (1:1) in specially designed cages
436 with a perforated plastic divider dividing the living space in half. This divider prevented direct
437 contact between the donor/primary infected and sentinel hamster and the movement of bedding
438 material. Regular bedding was replaced by alpha-dri bedding to avoid the generation of dust
439 particles. Donor hamsters were infected intranasally as described above and sentinel hamsters
440 placed on the other side of a divider afterwards. Hamsters were followed as described above
441 until 21 DPI. Experiments were performed with cages placed into a standard rodent cage rack,

442 under normal airflow conditions (Fig 5 c, d, e). Sentinels were either placed in the direction of
443 the airflow, or against it (Fig 5 b).

444

445 *Fomite Transmission experiments*

446 Fomite transmission was examined by infecting donor hamsters as described above by I.N.
447 inoculation. Two animals per cage were housed for 4 days. Regular bedding was replaced by
448 alpha-dri bedding to avoid the generation of dust particles. At 4 DPI, donors were euthanized,
449 and sentinel animals (2 animals per cage) were placed into the contaminated cage (Fig 5 a).
450 Hamsters were followed as described above until DPI 21; bedding and cages were left
451 undisturbed.

452

453 *Particle sizing*

454 Transmission cages were modified by introducing an inlet on the side of the infected hamster
455 side, and sample ports on each end of the cage for measurement of particles in the air under
456 constant airflow condition. Particles were generated by spraying a 20% (v/v) glycerol solution
457 with a standard spray bottle through the cage inlet. The particle size range of the generated
458 particles was measured using a Model 3321 aerodynamic particle sizer spectrometer (TSI). The
459 cage was coated with two sprays at an interval of 30 seconds (s) and after a third spray the
460 sample port was opened, and a sample was analyzed. The cage was sprayed every 30 s and
461 five samples were analysed (5 runs, each 60 s) for both donor side (primary infected side) and
462 sentinel side.

463

464 *Histopathology and immunohistochemistry*

465 Necropsies and tissue sampling were performed according to IBC-approved protocols. Tissues
466 were fixed for a minimum of 7 days in 10% neutral buffered formalin with 2 changes. Tissues
467 were placed in cassettes and processed with a Sakura VIP-6 Tissue Tek, on a 12-hour
468 automated schedule, using a graded series of ethanol, xylene, and ParaPlast Extra. Prior to
469 staining, embedded tissues were sectioned at 5 μ m and dried overnight at 42°C. Using
470 GenScript U864YFA140-4/CB2093 NP-1 (1:1000) specific anti-CoV immunoreactivity was
471 detected using the Vector Laboratories ImPress VR anti-rabbit IgG polymer (# MP-6401) as
472 secondary antibody. The tissues were then processed using the Discovery Ultra automated
473 processor (Ventana Medical Systems) with a ChromoMap DAB kit Roche Tissue Diagnostics
474 (#760-159).

475

476 *Viral RNA detection*

477 Swabs from hamsters were collected as described above. Cage and bedding material were
478 sampled with prewetted swabs in 1 mL of DMEM supplemented with 200 U/mL penicillin and
479 200 μ g/mL streptomycin. Then, 140 μ L was utilized for RNA extraction using the QIAamp Viral
480 RNA Kit (Qiagen) using QIAcube HT automated system (Qiagen) according to the
481 manufacturer's instructions with an elution volume of 150 μ L. Sub-genomic (sg) viral RNA and
482 genomic (g) was detected by qRT-PCR [27, 61]. Five μ L RNA was tested with TaqMan™ Fast
483 Virus One-Step Master Mix (Applied Biosystems) using QuantStudio 6 Flex Real-Time PCR
484 System (Applied Biosystems) according to instructions of the manufacturer. Ten-fold dilutions of
485 SARS-CoV-2 standards with known copy numbers were used to construct a standard curve and
486 calculate copy numbers/mL.

487

488 *Viral titration*

489 Viable virus in tissue samples was determined as previously described [62]. In brief, lung,
490 trachea, brain, and gastrointestinal tissue samples were weighted, then homogenized in 1 mL of

491 DMEM (2% FBS). VeroE6 cells were inoculated with ten-fold serial dilutions of tissue
492 homogenate, incubated 1 h at 37°C, the first two dilutions washed twice with 2% DMEM. Cells
493 were incubated with tissue homogenate for 6 days, then scored for cytopathic effect. TCID₅₀/mL
494 was calculated by the method of Spearman-Kärber and adjusted for tissue weight.

495

496 *Serology*

497 Serum samples were inactivated with γ -irradiation (2 mRad) and analyzed as previously
498 described [63]. In brief, maxisorp plates (Nunc) were coated with 50 ng spike protein (generated
499 in-house) per well and incubated overnight at 4°C. After blocking with casein in phosphate
500 buffered saline (PBS) (ThermoFisher) for 1 h at room temperature (RT), serially diluted 2-fold
501 serum samples (duplicate, in blocking buffer) were incubated for 1 h at RT. Spike-specific
502 antibodies were detected with goat anti-hamster IgG Fc (horseradish peroxidase (HRP)-
503 conjugated, Abcam) for 1 h at RT and visualized with KPL TMB 2-component peroxidase
504 substrate kit (SeraCare, 5120-0047). The reaction was stopped with KPL stop solution
505 (Seracare) and read at 450 nm. Plates were washed 3 to 5 x with PBS-T (0.1% Tween) for each
506 wash. The threshold for positivity was calculated as the average plus 3 x the standard deviation
507 of negative control hamster sera.

508

509 *Cytokine analysis*

510 Cytokine concentrations were determined using a commercial hamster ELISA kit for TNF- α ,
511 INF- γ , IL-6, IL-4, and IL-10 available at antibodies.com, according to the manufacturer's
512 instructions (antibodies.com; A74292, A74590, A74291, A74027, A75096). Samples were pre-
513 diluted 1:50.

514

515 *Statistical Analysis*

516 Heatmaps and correlation graphs were made in R [64] using pheatmap [65] and corrplot [66]
517 packages. Significance test were performed as indicated where appropriate: Spearman
518 correlation test, two-way ANOVA and Kruskal-Wallis test. Statistical significance levels were
519 determined as follows: ns = $p > 0.05$; * = $p \leq 0.05$; ** = $p \leq 0.01$; *** = $p \leq 0.001$; **** = $p \leq$
520 0.0001.

521

522 **Acknowledgements**

523 The authors would like to thank the Rocky Mountain Veterinary branch, including Nicki Arndt,
524 Amanda Weidow and Brian Mosbrucker for assistance with high containment husbandry and
525 cage design and testing, Greg Saturday for assistance with necropsy, Tina Thomas for
526 assistance with histology, Stephanie Seifert for assistance in study protocol editing, and Rose
527 Perry and Ryan Kissinger for assistance with the figures. This research was supported by the
528 Intramural Research Program of the National Institute of Allergy and Infectious Diseases
529 (NIAID), National Institutes of Health (NIH).

530

531 **Disclosure statement**

532 The authors declare no competing financial interests.

533

534 **References**

- 535 1. WHO, *Coronavirus disease 2019 (COVID-19) Situation Report – 52*. 2020.
- 536 2. Nie, S., et al., *Coronavirus Disease 2019-related dyspnea cases difficult to interpret using chest*
537 *computed tomography*. *Respiratory medicine*, 2020. **167**: p. 105951-105951.
- 538 3. Parry, A.H., et al., *Spectrum of chest computed tomographic (CT) findings in coronavirus*
539 *disease-19 (COVID-19) patients in India*. *European Journal of Radiology*, 2020. **129**: p. 109147-109147.
- 540 4. van Kampen, J.J.A., et al., *Shedding of infectious virus in hospitalized patients with coronavirus*
541 *disease-2019 (COVID-19): duration and key determinants*. *medRxiv*, 2020: p. 2020.06.08.20125310.
- 542 5. Cevik, M., et al., *SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral*
543 *shedding, and infectiousness: a systematic review and meta-analysis*. *The Lancet Microbe*, 2020.

- 544 6. Organization, W.H., *Transmission of SARS-CoV-2: implications for infection prevention*
545 *precautions*. 2020.
- 546 7. van Doremalen, N., et al., *Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-*
547 *CoV-1*. *N Engl J Med*, 2020. **382**(16): p. 1564-1567.
- 548 8. Chia, P.Y., et al., *Detection of air and surface contamination by SARS-CoV-2 in hospital rooms*
549 *of infected patients*. *Nat Commun*, 2020. **11**(1): p. 2800.
- 550 9. Guo, Z.D., et al., *Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome*
551 *Coronavirus 2 in Hospital Wards, Wuhan, China, 2020*. *Emerg Infect Dis*, 2020. **26**(7): p. 1583-1591.
- 552 10. Zhou, J., et al., *Investigating SARS-CoV-2 surface and air contamination in an acute healthcare*
553 *setting during the peak of the COVID-19 pandemic in London*. medRxiv, 2020: p. 2020.05.24.20110346.
- 554 11. Pastorino, B., et al., *Prolonged Infectivity of SARS-CoV-2 in Fomites*. *Emerg Infect Dis*, 2020.
555 **26**(9): p. 2256-7.
- 556 12. Matson, M.J., et al., *Effect of Environmental Conditions on SARS-CoV-2 Stability in Human*
557 *Nasal Mucus and Sputum*. *Emerg Infect Dis*, 2020. **26**(9): p. 2276-8.
- 558 13. Bohannon, J.K., et al., *Generation and characterization of large-particle aerosols using a center*
559 *flow tangential aerosol generator with a non-human-primate, head-only aerosol chamber*. *Inhal Toxicol*,
560 2015. **27**(5): p. 247-53.
- 561 14. Cheng, V.C., et al., *Air and environmental sampling for SARS-CoV-2 around hospitalized*
562 *patients with coronavirus disease 2019 (COVID-19)*. *Infect Control Hosp Epidemiol*, 2020. **41**(11): p.
563 1258-1265.
- 564 15. Liu, Y., et al., *Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals*. *Nature*, 2020.
565 **582**(7813): p. 557-560.
- 566 16. Lu, J., et al., *COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou,*
567 *China, 2020*. *Emerg Infect Dis*, 2020. **26**(7): p. 1628-1631.
- 568 17. Ma, J., et al., *Exhaled breath is a significant source of SARS-CoV-2 emission*. medRxiv, 2020: p.
569 2020.05.31.20115154.
- 570 18. Miller, S.L., et al., *Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the*
571 *Skagit Valley Chorale superspreading event*. *Indoor Air*, 2020.
- 572 19. National Academies of Sciences, E. and Medicine, *Airborne Transmission of SARS-CoV-2:*
573 *Proceedings of a Workshop—in Brief*, ed. M. Shelton-Davenport, et al. 2020, Washington, DC: The
574 National Academies Press. 18.
- 575 20. Santarpia, J.L., et al., *Aerosol and Surface Transmission Potential of SARS-CoV-2*. medRxiv,
576 2020: p. 2020.03.23.20039446.

- 577 21. Lednicky, J.A., et al., *Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients.*
578 *International Journal of Infectious Diseases*, 2020. **100**: p. 476-482.
- 579 22. Santarpia, J.L., et al., *Aerosol and surface contamination of SARS-CoV-2 observed in quarantine*
580 *and isolation care.* *Scientific Reports*, 2020. **10**(1): p. 12732.
- 581 23. Colaneri, M., et al., *Severe acute respiratory syndrome coronavirus 2 RNA contamination of*
582 *inanimate surfaces and virus viability in a health care emergency unit.* *Clinical Microbiology and*
583 *Infection*, 2020. **26**(8): p. 1094.e1-1094.e5.
- 584 24. Rosenke, K., et al., *Defining the Syrian hamster as a highly susceptible preclinical model for*
585 *SARS-CoV-2 infection.* *Emerg Microbes Infect*, 2020: p. 1-36.
- 586 25. Sia, S.F., et al., *Pathogenesis and transmission of SARS-CoV-2 in golden hamsters.* *Nature*, 2020.
- 587 26. Chan, J.F.-W., et al., *Simulation of the Clinical and Pathological Manifestations of Coronavirus*
588 *Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis*
589 *and Transmissibility.* *Clinical Infectious Diseases*, 2020.
- 590 27. Corman, V.M., et al., *Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.*
591 *Euro Surveill*, 2020. **25**(3).
- 592 28. Sun, K., et al., *Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2.*
593 *Science*, 2020.
- 594 29. Muñoz-Fontela, C., et al., *Animal models for COVID-19.* *Nature*, 2020. **586**(7830): p. 509-515.
- 595 30. Guan, W.J., et al., *Comorbidity and its impact on 1590 patients with COVID-19 in China: a*
596 *nationwide analysis.* *Eur Respir J*, 2020. **55**(5).
- 597 31. Bryche, B., et al., *Massive transient damage of the olfactory epithelium associated with infection*
598 *of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters.* *Brain Behav Immun*, 2020.
- 599 32. Chak-Yiu Lee, A., et al., *Oral SARS-CoV-2 inoculation establishes subclinical respiratory*
600 *infection with virus shedding in golden Syrian hamsters.* *Cell Rep Med*, 2020: p. 100121.
- 601 33. Osterrieder, N., et al., *Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters.*
602 *Viruses*, 2020. **12**(7).
- 603 34. Hammoud, D.A., et al., *Aerosol exposure to intermediate size Nipah virus particles induces*
604 *neurological disease in African green monkeys.* *PLOS Neglected Tropical Diseases*, 2018. **12**(11): p.
605 e0006978.
- 606 35. Lee, J.H., et al., *The Use of Large-Particle Aerosol Exposure to Nipah Virus to Mimic Human*
607 *Neurological Disease Manifestations in the African Green Monkey.* *The Journal of Infectious Diseases*,
608 2019. **221**(Supplement_4): p. S419-S430.
- 609 36. Leung, N.H.L., et al., *Respiratory virus shedding in exhaled breath and efficacy of face masks.*
610 *Nature Medicine*, 2020. **26**(5): p. 676-680.

- 611 37. Konda, A., et al., *Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth*
612 *Masks*. ACS Nano, 2020. **14**(5): p. 6339-6347.
- 613 38. Kähler, C.J. and R. Hain, *Fundamental protective mechanisms of face masks against droplet*
614 *infections*. J Aerosol Sci, 2020. **148**: p. 105617.
- 615 39. Gandhi, M. and G.W. Rutherford, *Facial Masking for Covid-19 — Potential for “Variolation” as*
616 *We Await a Vaccine*. New England Journal of Medicine, 2020. **383**(18): p. e101.
- 617 40. Byambasuren, O., et al., *Estimating the extent of asymptomatic COVID-19 and its potential for*
618 *community transmission: Systematic review and meta-analysis*. Official Journal of the Association of
619 Medical Microbiology and Infectious Disease Canada, 2020. **COVID-19**: p. Accepted version,
620 e20200030.
- 621 41. He, G., et al., *The clinical feature of silent infections of novel coronavirus infection (COVID-19)*
622 *in Wenzhou*. Journal of Medical Virology, 2020. **92**(10): p. 1761-1763.
- 623 42. Rothe, C., et al., *Transmission of 2019-nCoV Infection from an Asymptomatic Contact in*
624 *Germany*. N Engl J Med, 2020. **382**(10): p. 970-971.
- 625 43. Meng, H., et al., *CT imaging and clinical course of asymptomatic cases with COVID-19*
626 *pneumonia at admission in Wuhan, China*. Journal of Infection, 2020. **81**(1): p. e33-e39.
- 627 44. Mizumoto, K., et al., *Estimating the asymptomatic proportion of coronavirus disease 2019*
628 *(COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020*.
629 *Eurosurveillance*, 2020. **25**(10): p. 2000180.
- 630 45. Bai, Y., et al., *Presumed Asymptomatic Carrier Transmission of COVID-19*. JAMA, 2020.
631 **323**(14): p. 1406-1407.
- 632 46. Bae, S.H., et al., *Asymptomatic Transmission of SARS-CoV-2 on Evacuation Flight*. Emerging
633 *Infectious Disease journal*, 2020. **26**(11): p. 2705.
- 634 47. Goldman, E., *Exaggerated risk of transmission of COVID-19 by fomites*. Lancet Infect Dis, 2020.
635 **20**(8): p. 892-893.
- 636 48. Judson, S.D. and V.J. Munster, *A framework for nosocomial transmission of emerging*
637 *coronaviruses*. Infect Control Hosp Epidemiol, 2020: p. 1-2.
- 638 49. Judson, S.D. and V.J. Munster, *Nosocomial Transmission of Emerging Viruses via Aerosol-*
639 *Generating Medical Procedures*. Viruses, 2019. **11**(10).
- 640 50. Kutter, J.S., et al., *SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets*
641 *over more than one meter distance*. bioRxiv, 2020: p. 2020.10.19.345363.
- 642 51. Richard, M., et al., *SARS-CoV-2 is transmitted via contact and via the air between ferrets*. Nat
643 *Commun*, 2020. **11**(1): p. 3496.

- 644 52. Chan, J.F., et al., *Surgical mask partition reduces the risk of non-contact transmission in a golden*
645 *Syrian hamster model for Coronavirus Disease 2019 (COVID-19)*. Clin Infect Dis, 2020.
- 646 53. Hamner, L., et al., *High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice -*
647 *Skagit County, Washington, March 2020*. MMWR. Morbidity and mortality weekly report, 2020. **69**(19):
648 p. 606-610.
- 649 54. Leclerc, Q.J., et al., *What settings have been linked to SARS-CoV-2 transmission clusters? :*
650 Wellcome Open Res. 2020 Jun 5;5:83. doi: 10.12688/wellcomeopenres.15889.2. eCollection 2020.
- 651 55. Morawska, L., et al., *How can airborne transmission of COVID-19 indoors be minimised?*
652 Environment international, 2020. **142**: p. 105832-105832.
- 653 56. CDC, *Ventilation*. 2020.
- 654 57. Hou, Y.J., et al., *SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and*
655 *transmission in vivo*. Science, 2020.
- 656 58. de Wit, E., et al., *The Middle East respiratory syndrome coronavirus (MERS-CoV) does not*
657 *replicate in Syrian hamsters*. PLoS One, 2013. **8**(7): p. e69127.
- 658 59. Alexander, D.J., et al., *Association of Inhalation Toxicologists (AIT) working party*
659 *recommendation for standard delivered dose calculation and expression in non-clinical aerosol*
660 *inhalation toxicology studies with pharmaceuticals*. Inhal Toxicol, 2008. **20**(13): p. 1179-89.
- 661 60. Hartings, J.M. and C.J. Roy, *The automated bioaerosol exposure system: preclinical platform*
662 *development and a respiratory dosimetry application with nonhuman primates*. J Pharmacol Toxicol
663 Methods, 2004. **49**(1): p. 39-55.
- 664 61. Corman, V.M., et al., *Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR*.
665 Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease
666 bulletin, 2020. **25**(3): p. 2000045.
- 667 62. van Doremalen, N., et al., *Efficacy of antibody-based therapies against Middle East respiratory*
668 *syndrome coronavirus (MERS-CoV) in common marmosets*. Antiviral Res, 2017. **143**: p. 30-37.
- 669 63. Yinda, C.K., et al., *K18-hACE2 mice develop respiratory disease resembling severe COVID-19*.
670 bioRxiv, 2020.
- 671 64. R Development Core Team, *R: A language and Environment for Statistical computing* 2010, R
672 Foundation for Statistical Computing.
- 673 65. Kolde, R., *Implementation of heatmaps that offers more control over dimensions and*
674 *appearance*. 2019.
- 675 66. Wei, T. and V. Simko, *R package "corrplot": Visualization of a Correlation Matrix*. 2017.
676
677

678

679 **Figure Legends**

680 **Figure 1. Disease severity in Syrian hamsters. a.** Experimental layout for intranasal (I.N.),
681 fomite and aerosol exposure experiments. White circle: inoculation, black: necropsy, grey, swab
682 time-points **b.** Relative weight loss in hamsters after SARS-CoV-2 inoculation over time (DPI =
683 day post inoculation, $n = 4$ per group). The lines represent mean \pm SEM. Black line indicates
684 weights of unexposed control group. Dotted vertical line represent averaged peak weight loss
685 post inoculation or exposure. Statistical significance was measured using a Mann–Whitney two-
686 sided test, p-values are shown. **c.** Violin plot with individuals and median of weight gain at 14
687 DPI. Statistical significance was measured using a Kruskal-Wallis test, followed by Dunn's
688 multiple comparison test. **d.** Violin plot with individual and median titers of infectious SARS-CoV-
689 2 in the respiratory and intestinal tissues at 1 DPI and **e.** 4 DPI, Red: I.N, blue: aerosol, purple:
690 fomite, black: unexposed; dotted horizontal line = limit of detection (0.5). GI = gastrointestinal
691 tract; $n = 4$ per group. Statistical significance was measured using a two-way ANOVA, followed
692 by Tukey's multiple comparison test. * $P < 0.05$, ** $P < 0.001$, *** $P < 0.0001$, **** $P < 0.0001$. NS,
693 not significant.

694

695 **Figure 2. Comparison of early replication of SARS-CoV-2 in respiratory tract**

696 Comparison of replication of SARS-CoV-2 for intranasal (I.N.), aerosol and fomite inoculated
697 hamsters at 1 day post inoculation (DPI) by immunohistochemistry **a, b, c.** SARS-CoV-2 antigen
698 detection in ciliated epithelial cells of the nasal mucosa (200x). **d.** Nasal mucosa from a control
699 hamster (200x). **e, f, g.** SARS-CoV-2 antigen detection throughout tracheal ciliated epithelial
700 cells (400x). **h.** Normal tracheal mucosa from a control hamster. **i.** SARS-CoV-2 antigen
701 detection focused on terminal bronchioles and adjacent alveolar spaces (100x). **j.** Lack of
702 SARS-CoV-2 in epithelial cells with strong antigen detection noted in pulmonary macrophages
703 (inset) (100x). **k.** Lack of SARS-CoV-2 antigen detection throughout the lung (100x). **l.** Normal
704 lung from control hamster (100x). **m.** Quantitative comparison of antigen detection for lung (type
705 I and type II pneumocytes, macrophages (mos), mucosa of the trachea and skull sections
706 (olfactory and ciliated epithelium of the nasal turbinates) at 1 day post inoculation for I.N.,
707 aerosol, fomite, and control groups.

708

709 **Figure 3: Comparison of the respiratory tract pathology of SARS-CoV-2 Infected** 710 **hamsters**

711 Comparison of SARS-CoV-2 pathology for intranasal (I.N.), aerosol and fomite inoculated
712 hamsters at 4 day post inoculation (DPI) **a.** Infiltration and disruption of the ciliated nasal
713 mucosa by moderate numbers of leukocytes with multifocal epithelial cell necrosis (200x). **b.**
714 Multifocal disruption of the nasal ciliated mucosa by low numbers of leukocytes with
715 accumulations of degenerate leukocytes in the nasal passage (200x). **c.** Intact ciliated nasal
716 mucosa with normal mucus presence within the lumen (200x). **d.** A control nasal turbinate with
717 intact ciliated nasal mucosa and mucus within the lumen (200x). **e.** Disruption of the tracheal
718 mucosa with single cell necrosis and infiltration by low numbers of leukocytes (400x). **f.**
719 Unaffected tracheal mucosa (400x). **g.** Unaffected tracheal mucosa (400x). **h.** Section of
720 tracheal mucosa from a control hamster (400x). **i-l.** No significant histopathologic lesions in the
721 lung of any inoculation route at 1 day-post-inoculation (100x). **m.** Multifocal disruption of ciliated
722 nasal mucosa with accumulation of cellular debris and degenerate leukocytes within the nasal
723 passage (200x). **n.** Severe disruption and multifocal erosion of the nasal mucosa with
724 accumulation of numerous degenerate leukocytes and abundant cellular debris within the nasal
725 passage (200x). **o.** Ciliated epithelial cell degeneration and mucosal erosion with leukocyte
726 infiltration into the lamina propria (200x). **p.** Normal nasal turbinate from a control hamster
727 (200x). **q.** Focal disruption of the tracheal mucosa by low numbers of leukocytes (400x). **r.**
728 Multifocal infiltration of the mucosa by moderate numbers of leukocytes and multifocal epithelial
729 cell necrosis (400x). **s.** Multifocal loss of epithelial cilia and infiltration of the lamina propria by
730 moderate numbers of leukocytes (400x). **t.** Normal tracheal mucosa from a control hamster
731 (400x). **u.** Widespread, moderate to severe broncho-interstitial pneumonia (100x). **v.** Multifocal
732 moderate broncho-interstitial pneumonia focused on terminal bronchioles (100x). **w.** Multifocal,
733 mild interstitial pneumonia focused on terminal bronchioles (100x). **x.** Normal lung from a control
734 hamster (100x). **y,z.** Clustering (Euclidean, complete) of animals based in viral titers in lung and
735 trachea and quantitative assessment of pathology in the upper and lower respiratory tract on 1
736 DPI and 4 DPI. Heatmap colors refer to color scale on the right, grey = NA. Exposure route is
737 indicated by color bar at the top.

738

739 **Figure 4. Exposure dependent SARS-CoV-2 acute systemic cytokine response, strength**
740 **of humoral response and viral shedding profile. a.** Violin plots with individuals and median of
741 serum concentrations of key cytokines (interferon (IFN)- γ , tumour necrosis factor (TNF)- α ,
742 interleukin (IL)-6, IL-4, and IL-10) on 4 days post inoculation (DPI). **b.** Violin plots with
743 individuals and median of endpoint IgG antibody titres against SARS-CoV-2 spike ectodomain
744 measured by ELISA in serum. ELISAs were done once. **c.** Respiratory and **d.** intestinal viral






745 shedding of I.N., aerosol and fomite exposed hamsters. Median, 95% CI and individuals are
746 shown. **e.** Peak shedding and **f.** cumulative (area under the curve (AUC) analysis) respiratory
747 and intestinal shedding of I.N., aerosol and fomite exposed hamsters. Statistical significance
748 was measured by Kruskal-Wallis test, $n = 4$ per group. $*P < 0.05$, $**P < 0.001$, $***P < 0.0001$,
749 $****P < 0.0001$. NS, not significant. **g.** Correlation between cytokine levels, early shedding (2
750 DPI), peak shedding, peak weight loss, lung titers and pathology at 4 DPI. Significant
751 correlations ($n = 4$ per group, Pearson-Spearman analysis, $p < 0.05$) are indicated with an
752 asterisk and strength of correlation (R^2) is depicted according to the colour bar on the right.


753
754 **Figure 5. Fomite and airborne transmission in the Syrian hamster.** **a.** Experimental layout
755 for fomite and **b.** airborne exposure experiments in hamsters. **c.** Pictures of smoke test to
756 demonstrate unidirectional airflow in the transmission cage. **d.** Aerodynamic particle size
757 distribution on either side of the transmission cage. **e.** Reduction of particles by the divider. **f, g.**
758 Relative weight loss in hamsters after SARS-CoV-2 transmission via fomite and airborne routes.
759 Lines represent mean \pm SEM. **h.** Violin plot with individuals and median of endpoint IgG
760 antibody titres against SARS-CoV-2 spike ectodomain by ELISA in serum of hamsters infected
761 through airborne and fomite transmission route. ELISAs were done once. **i.** Respiratory
762 shedding profile of hamsters exposed through fomite and airborne transmission routes,
763 individuals, median and 95% CI are shown. **j.** cumulative (area under the curve (AUC) analysis)
764 of respiratory shedding from animals which seroconverted after airborne and fomite
765 transmission. Violin plots with individuals and median are depicted. Statistical significance was
766 measured by Kruskal-Wallis test, $n = 8$ per group. $*P < 0.05$, $**P < 0.001$, $***P < 0.0001$, $****P <$
767 0.0001 . NS, not significant.

768

769 **Supplemental legend**

770 **Supplemental Figure 1:** **a.** Violin plot of infectious SARS-CoV-2 titer in the lungs of all animals
771 at 14 or 21 DPI. **b.** cage and **c.** bedding contamination by infected animals till 7 DPI.

a**b****c****d****e**



m

	Aerosol	I.N.	Fomite	Control
Lung				
Bronchioles	++	-	-	-
Type I	+	-	-	-
Type II	-/+	-	-	-
Mos	+	-/+	-	-
Trachea				
Mucosa	++	-	-	-
Skull				
Ciliated	++	+/++	-/+	-
Olfactory	+	-/+	-	-

